Last reviewed · How we verify
NCT06795594
Effectiveness of Cheek Acupuncture Therapy for Pain Control After Cesarean Delivery
NA trial testing cheek acupuncture in Acupuncture Analgesia in 80 participants. Completed in 10 March 2025.
10 March 2025
Quick facts
| Lead sponsor | Beijing Tongren Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 5 January 2025 |
| Primary completion | 10 March 2025 |
| Estimated completion | 10 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- cheek acupuncture
- sufentanil 2 µg/kg + ondansetron 0.2 mg/kg — full drug profile →
Conditions studied
- Acupuncture Analgesia — all drugs for Acupuncture Analgesia →
Sponsor
Beijing Tongren Hospital
Who can join
Adults 18 to 45, female only, with Acupuncture Analgesia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates whether cheek acupuncture therapy can alleviate postoperative pain in cesarean section patients and explores its mechanisms of action through a prospective randomized controlled clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06795594
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of cheek acupuncture
Trials testing the same drug.
- NCT06001112 — Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis · NA · completed
- NCT05923021 — Moderate Depressive Disorder With Cheek Acupuncture · NA · unknown
Other recruiting trials for Acupuncture Analgesia
Currently open trials in the same condition.
- NCT07123805 — ACU_Knee: Role of Acupuncture in Knee Prosthetic Surgery · NA · recruiting
Other Beijing Tongren Hospital trials
Trials by the same sponsor.
- NCT07499791 — Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis · Phase 2 · not yet recruiting
- NCT07524959 — Antagonism of Neostigmine in Continuous Infusion of Mivacurium · NA · not yet recruiting
- NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
- NCT07472764 — Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children · NA · not yet recruiting
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06795594 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tongren Hospital
- Last refreshed: 25 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06795594.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing